Abstract
The Authors report the results of a retrospective study concerning the use of mitomycin C in the prophylactic treatment of superficial bladder cancer after trans-urethral resection. The series includes 113 patients; minimum follow-up: 6 months, maximum 54, mean 17.7 months. Recurrence and progression rate was evaluated at 6, 12, 24, and 36 months. The cumulative recurrence and progression rate was 16.8% and 6.1% respectively. Patients with pTa neoplasms didn't develop progressions. G2 and G3 carcinoma recurrence and progression rate was higher than with G1 tumours. Multifocal neoplasms showed a higher trend recurrence compared to solitary tumours. The number of recurrences in the patient group with primitive neoplasms was not significantly different from that of patients with recurrent carcinoma.
Get full access to this article
View all access options for this article.